Occlutech, a Helsingborg, Sweden-based developer of medical implants treating structural heart diseases, has received a €15m equity investment.
The round was led by Hong Kong-based Interlink Investments Ltd., with participation from investors and Occlutech distribution partners from Japan, Switzerland, Ireland, Austria and Turkey.
The company intends to use the funds to accelerate R&D and bring new products to the market in the near future.
Founded in 2003 and led by CEO Tor Peters, Occlutech specializes in developing and manufacturing cardiac occlusion devices and other vascular implants treating diseases such as atrial septal defect (ASD) patent foramen ovale (PFO) and left atrial appendage (LAA).
FinSMEs
24/08/2011